Pulocimab

• UNSPSC Description:

  Pulocimab is an anti-VEGFR2 monoclonal antibody (mAb). Pulocimab can be used for the research of cancers[1].

• Target Antigen:

  VEGFR

• Type:

  Inhibitory Antibodies

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/pulocimab.html

• Solubility:

  10 mM in DMSO

• Smiles:

  [Pulocimab]

• References & Citations:

  [1]Keam SJ. Cadonilimab: First Approval. Drugs. 2022 Aug;82(12):1333-1339.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 3

• CAS Number:

  2428381-49-9